0
Article |

A Case of Xeroderma Pigmentosum Group A Diagnosed With a Polymerase Chain Reaction (PCR) Technique: Title and subTitle BreakUsefulness of PCR in the Detection of Point Mutation in a Patient With a Hereditary Disease

Satoshi Kore-eda, MD; Toshihiro Tanaka, MD, PhD; Shin-ichi Moriwaki, MD; Chikako Nishigori, MD, PhD; Sadao Imamura, MD, PhD
[+] Author Affiliations

Accepted for publication January 21, 1992.

Reprint requests to Department of Dermatology, Faculty of Medicine, Kyoto University, Shogoin, Sakyo-ku, Kyoto 606, Japan (Dr Tanaka).


From the Department of Dermatology, Faculty of Medicine, Kyoto (Japan) University.


Arch Dermatol. 1992;128(7):971-974. doi:10.1001/archderm.1992.01680170103016
Text Size: A A A
Published online

• Background.—  The gene responsible for the xeroderma pigmentosum (XP) group A gene was recently identified and isolated. Preliminary study with fibroblasts from patients with XP group A revealed that most of the Japanese patients with XP group A have a point mutation at the 3′ splice acceptor site of intron 3. This mutation site in the XP group A—complementing gene can be recognized by a restriction enzyme, AlwNI. This article describes the usefulness of the polymerase chain reaction diagnosis on XP group A.

Observations.—  We tried a polymerase chain reaction diagnosis on genomic DNA from a sporadic case of XP group A and this child's parents. AlwNI restriction fragment length polymorphism of the polymerase chain reaction product showed three bands for his father's and mother's DNA, one corresponding to normal and two corresponding to a point-mutated gene, respectively. A DNA sample from our patient showed two fragments indicating that only he has the mutated gene.

Conclusions.—  This study demonstrated that we can know that this patient has group A XP without a complementation test that needs a lot of time. Moreover, our study revealed that we can detect the hidden mutated XP group A—complementing gene in the pedigree in which there is no patient with XP. Furthermore, it may be available soon for prenatal diagnosis.(Arch Dermatol. 1992;128:971-974)

REFERENCES

Kraemer KH, Lee MM, Scotto J.  Xeroderma pigmentosum . Arch Dermatol. 1987;;123:241-250.
Takebe H, Nishigori C, Satoh Y.  Genetics and skin cancer of xeroderma pigmentosum in Japan . Jpn J Cancer Res. 1987;;78:1135-1143.
Tanaka K, Satokata I, Ogita Z, Uchida T, Okada Y.  Molecular cloning of a mouse DNA repair gene that complements the defect of group-A xeroderma pigmentosum . Proc Natl Acad Sci U S A. 1989;;86:5512-5516.
Tanaka K, Miura N, Satokata I, et al.  Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain . Nature . 1990;;348:73-76.
Satokata I, Tanaka K, Miura N, et al.  Characterization of a splicing mutation in group A xeroderma pigmentosum . Proc Natl Acad Sci U S A. 1990;; 87:9908-9912.
Iwai K, Tanaka K.  Molecular analysis of group A xeroderma pigmentosum . J Dermatol Sci. 1991;;2:198.
Moriwaki S, Nishigori C, Toda K, Imamura S, Takebe H.  DNA repair retardation in the cellular response to ultraviolet light in amyloidosis cutis dyschromica . J Dermatol Sci. 1990;;1:402.
Tanaka T, Takahashi K, Ideyama S, Imamura S, Noma T.  Demonstration of clonal proliferation of T lymphocytes in early neoplastic disease . J Am Acad Dermatol. 1989;;21:218-223.
Saiki RK, Gelfand DH, Stoffel S, et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase . Science . 1988;;239:487-491.
Nishigori C, Miyachi Y, Imamura S, Takebe H.  Reduced superoxide dismutase activity in xeroderma pigmentosum fibroblasts . J Invest Dermatol. 1989;;93:506-510.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Kraemer KH, Lee MM, Scotto J.  Xeroderma pigmentosum . Arch Dermatol. 1987;;123:241-250.
Takebe H, Nishigori C, Satoh Y.  Genetics and skin cancer of xeroderma pigmentosum in Japan . Jpn J Cancer Res. 1987;;78:1135-1143.
Tanaka K, Satokata I, Ogita Z, Uchida T, Okada Y.  Molecular cloning of a mouse DNA repair gene that complements the defect of group-A xeroderma pigmentosum . Proc Natl Acad Sci U S A. 1989;;86:5512-5516.
Tanaka K, Miura N, Satokata I, et al.  Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain . Nature . 1990;;348:73-76.
Satokata I, Tanaka K, Miura N, et al.  Characterization of a splicing mutation in group A xeroderma pigmentosum . Proc Natl Acad Sci U S A. 1990;; 87:9908-9912.
Iwai K, Tanaka K.  Molecular analysis of group A xeroderma pigmentosum . J Dermatol Sci. 1991;;2:198.
Moriwaki S, Nishigori C, Toda K, Imamura S, Takebe H.  DNA repair retardation in the cellular response to ultraviolet light in amyloidosis cutis dyschromica . J Dermatol Sci. 1990;;1:402.
Tanaka T, Takahashi K, Ideyama S, Imamura S, Noma T.  Demonstration of clonal proliferation of T lymphocytes in early neoplastic disease . J Am Acad Dermatol. 1989;;21:218-223.
Saiki RK, Gelfand DH, Stoffel S, et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase . Science . 1988;;239:487-491.
Nishigori C, Miyachi Y, Imamura S, Takebe H.  Reduced superoxide dismutase activity in xeroderma pigmentosum fibroblasts . J Invest Dermatol. 1989;;93:506-510.

Correspondence

CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.